Hepatitis C drugs reporting ‘flawed and misleading’
The mainstream media has been slammed over its coverage of a recent report linking the new hepatitis C medications with liver failure and other serious side-effects.
Professor Gregory Dore, head of the viral hepatitis clinical research program at the Kirby Institute, said the story was a “beat up”, based on a “completely flawed” report of post-licensing adverse event data.
But outlets such as the New York Times, which ran the story with the headline “Are new drugs for hepatitis C safe? A report raises concerns”, were misleading patients and their reporting would spark unnecessary fears, he said.
Looking at FDA adverse data for the 12 months ending on June 30, 2016, the Institute for Safe Medication Practices report found 761 reports in which antivirals failed to work.